Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALRNNASDAQ:ESPRNASDAQ:INBXNASDAQ:INMB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALRNAileron Therapeutics$2.52$1.61▼$4.50$45.72M2.2483,622 shs63,385 shsESPREsperion Therapeutics$1.00+4.1%$1.34$0.82▼$3.94$198.03M0.865.66 million shs5.25 million shsINBXInhibrx$12.33+5.2%$12.97$10.80▼$34.75$178.49MN/A196,971 shs103,133 shsINMBINmune Bio$7.86+0.1%$7.76$4.32▼$12.60$180.65M1.86252,093 shs166,958 shs20 Stocks to Sell NowGet This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALRNAileron Therapeutics0.00%0.00%0.00%0.00%-57.11%ESPREsperion Therapeutics+5.80%+3.25%-36.01%-49.21%-51.76%INBXInhibrx-5.10%-1.26%-17.00%-4.79%-65.69%INMBINmune Bio-0.63%+0.13%+4.39%-13.36%-33.31%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALRNAileron TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AESPREsperion Therapeutics3.4204 of 5 stars3.31.00.03.91.91.70.6INBXInhibrx2.5495 of 5 stars0.03.00.04.64.33.30.0INMBINmune Bio2.3938 of 5 stars3.61.00.00.03.81.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALRNAileron Therapeutics 4.00Strong BuyN/AN/AESPREsperion Therapeutics 2.50Moderate Buy$6.42542.05% UpsideINBXInhibrx 2.00HoldN/AN/AINMBINmune Bio 3.17Buy$22.80190.08% UpsideCurrent Analyst Ratings BreakdownLatest ALRN, INMB, ESPR, and INBX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/25/2025ESPREsperion TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.00 ➝ $5.004/25/2025ESPREsperion TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$16.00 ➝ $16.004/17/2025ESPREsperion TherapeuticsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$4.00 ➝ $3.004/8/2025ESPREsperion TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.00 ➝ $5.003/20/2025ESPREsperion TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$16.00 ➝ $16.003/4/2025ESPREsperion TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$16.00 ➝ $16.002/13/2025INMBINmune BioMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$22.00 ➝ $30.002/11/2025ESPREsperion TherapeuticsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$7.00 ➝ $4.002/11/2025ESPREsperion TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$16.00 ➝ $16.002/11/2025INMBINmune BioScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetSector Outperform ➝ Sector Outperform$22.00 ➝ $23.00(Data available from 4/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALRNAileron TherapeuticsN/AN/AN/AN/A$1.41 per shareN/AESPREsperion Therapeutics$332.31M0.60N/AN/A($3.85) per share-0.26INBXInhibrx$200K892.45N/AN/AN/A∞INMBINmune Bio$14K12,903.87N/AN/A$2.07 per share3.80Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALRNAileron Therapeutics-$15.73M-$3.120.00N/AN/AN/A-74.08%-27.93%N/AESPREsperion Therapeutics-$209.25M-$0.25N/AN/AN/A-29.37%N/A-10.77%5/6/2025 (Estimated)INBXInhibrx-$154.96MN/A0.00N/AN/AN/A-113.74%-80.56%6/16/2025 (Estimated)INMBINmune Bio-$30.01M-$2.11N/AN/AN/AN/A-117.48%-78.96%5/8/2025 (Estimated)Latest ALRN, INMB, ESPR, and INBX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025INMBINmune Bio-$0.43N/AN/AN/AN/AN/A5/6/2025Q1 2025ESPREsperion Therapeutics-$0.18N/AN/AN/A$54.97 millionN/A3/27/2025Q4 2024INMBINmune Bio-$0.54-$0.40+$0.14-$0.40N/AN/A3/17/2025Q4 2024INBXInhibrx-$2.88-$3.09-$0.21-$3.09N/A$0.10 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALRNAileron TherapeuticsN/AN/AN/AN/AN/AESPREsperion TherapeuticsN/AN/AN/AN/AN/AINBXInhibrxN/AN/AN/AN/AN/AINMBINmune BioN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALRNAileron TherapeuticsN/A3.303.30ESPREsperion TherapeuticsN/A1.851.37INBXInhibrxN/A4.704.70INMBINmune BioN/A2.592.59Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALRNAileron Therapeutics90.89%ESPREsperion Therapeutics47.39%INBXInhibrx82.46%INMBINmune Bio12.72%Insider OwnershipCompanyInsider OwnershipALRNAileron Therapeutics5.10%ESPREsperion Therapeutics1.00%INBXInhibrx22.20%INMBINmune Bio35.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALRNAileron Therapeutics921.67 million20.56 millionNot OptionableESPREsperion Therapeutics200198.15 million195.07 millionOptionableINBXInhibrx16614.48 million11.26 millionOptionableINMBINmune Bio1022.98 million14.37 millionOptionableALRN, INMB, ESPR, and INBX HeadlinesRecent News About These CompaniesWalleye Capital LLC Acquires New Shares in INmune Bio, Inc. (NASDAQ:INMB)April 29 at 3:57 AM | marketbeat.comDauntless Investment Group LLC Makes New $896,000 Investment in INmune Bio, Inc. (NASDAQ:INMB)April 26, 2025 | marketbeat.comINmune Bio to receive US patent for next-generation mesenchymal stromal cell product, CORDStromApril 19, 2025 | pharmabiz.comINmune Bio Receives Favorable Patentability Opinion for CORDStrom™ Platform TechnologyApril 16, 2025 | markets.businessinsider.comINmune Bio receives favorable patentability opinion for CORDStrom platformApril 16, 2025 | markets.businessinsider.comINmune Bio partners with Cell, Gene Therapy Catapult to scale up CORDStromApril 14, 2025 | markets.businessinsider.comINmune Bio Partners with Cell and Gene Therapy CatapultApril 14, 2025 | msn.comINmune Bio Partners with Cell and Gene Therapy Catapult to Scale Up CORDStrom™ Manufacturing for Commercial ReadinessApril 14, 2025 | globenewswire.comINmune Bio, Inc. (NASDAQ:INMB) Given Consensus Rating of "Buy" by BrokeragesApril 6, 2025 | marketbeat.comINmune Bio Inc. Presents Baseline Demographics and Disease Profiles of Participants in the MINDFuL Phase II StudyApril 1, 2025 | markets.businessinsider.comRaymond James Financial Inc. Takes Position in INmune Bio, Inc. (NASDAQ:INMB)March 31, 2025 | marketbeat.comINmune Bio, Inc. (NASDAQ:INMB) Q4 2024 Earnings Call TranscriptMarch 29, 2025 | msn.comINmune Bio, Inc.: INmune Bio Inc. Announces Year End 2024 Results and Provides a Business UpdateMarch 29, 2025 | finanznachrichten.deScotiabank Remains a Buy on Inmune Bio (INMB)March 29, 2025 | markets.businessinsider.comAlliance Global Partners Reaffirms Their Buy Rating on Inmune Bio (INMB)March 29, 2025 | markets.businessinsider.comINmune Bio, Inc. (INMB) Q4 2024 Earnings Call TranscriptMarch 27, 2025 | seekingalpha.comINmune Bio Inc. Announces Year End 2024 Results and Provides a Business UpdateMarch 27, 2025 | globenewswire.comWhat to Expect from INmune Bio's EarningsMarch 27, 2025 | benzinga.comINmune Bio: CORDstrom Is A Game-Changer, As Investors Await Alzheimer's ResultsMarch 18, 2025 | seekingalpha.comELEVAI Labs Inc. Ends License Agreement with INmuneMarch 3, 2025 | tipranks.comWhy INmune Bio, Inc. (INMB) is Skyrocketing So Far in 2025March 2, 2025 | insidermonkey.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesAre Tariffs Threatening Disney’s Comeback Story?By Jea Yu | April 9, 2025View Are Tariffs Threatening Disney’s Comeback Story?Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?By Jeffrey Neal Johnson | April 25, 2025View Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?Signs of a more buyer-friendly housing market emerge for the spring homebuying seasonBy The Associated Press | April 6, 2025View Signs of a more buyer-friendly housing market emerge for the spring homebuying season5 Highest-Rated Dividend Stocks According to MarketBeatBy Thomas Hughes | April 10, 2025View 5 Highest-Rated Dividend Stocks According to MarketBeatNewsmax’s IPO Whiplash: Meme Stock Hype or Growth Potential?By Jeffrey Neal Johnson | April 6, 2025View Newsmax’s IPO Whiplash: Meme Stock Hype or Growth Potential?ALRN, INMB, ESPR, and INBX Company DescriptionsAileron Therapeutics NASDAQ:ALRNAileron Therapeutics, Inc., a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company's lead product candidate is LTI-03, a peptide, which is in Phase 1b clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF). Its second product candidate is LTI-01, a proenzyme that has completed Phase 1b and Phase 2a clinical trials in LPE patients for the treatment of loculated pleural effusion. The company's pipeline also includes preclinical programs targeting cystic fibrosis and a peptide program focused on the caveolin-1 protein for systemic fibrosis indications. The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc. in February 2007. Aileron Therapeutics, Inc. was incorporated in 2001 and is headquartered in Austin, Texas.Esperion Therapeutics NASDAQ:ESPR$1.00 +0.04 (+4.12%) As of 04:00 PM EasternEsperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. The company's products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. The company has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.Inhibrx NASDAQ:INBX$12.33 +0.61 (+5.20%) As of 04:00 PM EasternInhibrx, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also develops INBRX-109, a tetravalent therapeutic candidate targeting death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, colorectal cancer, ewing sarcoma, and pancreatic adenocarcinoma; and INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company has license and collaboration agreements with 2seventy bio, Inc. and Bristol-Myers Squibb Company. Inhibrx, Inc. was incorporated in 2009 and is headquartered in La Jolla, California.INmune Bio NASDAQ:INMB$7.86 +0.01 (+0.13%) As of 04:00 PM EasternINmune Bio, Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, a mucinous polyglucan on the surface of some epithelial cancer cells that appears to predict resistant to immunotherapy, including women with MUC4 expressing HER2+ breast cancer and other MUC4 resistant cancers. It also provides XPro1595 for the treatment of Alzheimer's disease and treatment resistant depression. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; and University of Pittsburg. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Hims & Hers Stock Soars on Novo Nordisk Collaboration 3 Dividend Kings Outshining the Market in 2025 Tesla's Band-Aid Has Been Ripped Off: Rally Mode Engaged Amazon's Earnings Will Make or Break the Stock's Comeback Why D-Wave's Project With Davidson Is a Game-Changer For Quantum NXP Semiconductors: A Buy-and-Hold Stock in the Buy Zone Joby Aviation Shares Eye Breakout After Transition Flight Win Altria’s Resilient Strategy Keeps It a Top Dividend Play in 2025 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
